- Home
- BGI vs NXTC Comparison
BGI vs NXTC Comparison
Compare BGI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- NXTC
- Stock Information
- Founded
- BGI 1879
- NXTC 2015
- Country
- BGI Canada
- NXTC United States
- Employees
- BGI N/A
- NXTC N/A
- Industry
- BGI
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- NXTC Health Care
- Exchange
- BGI Nasdaq
- NXTC Nasdaq
- Market Cap
- BGI 22.7M
- NXTC 24.6M
- IPO Year
- BGI 2005
- NXTC 2019
- Fundamental
- Price
- BGI $1.09
- NXTC $9.82
- Analyst Decision
- BGI
- NXTC Strong Buy
- Analyst Count
- BGI 0
- NXTC 3
- Target Price
- BGI N/A
- NXTC $23.00
- AVG Volume (30 Days)
- BGI 47.9K
- NXTC 86.0K
- Earning Date
- BGI 11-26-2025
- NXTC 11-05-2025
- Dividend Yield
- BGI N/A
- NXTC N/A
- EPS Growth
- BGI N/A
- NXTC N/A
- EPS
- BGI N/A
- NXTC N/A
- Revenue
- BGI $124,446,731.00
- NXTC N/A
- Revenue This Year
- BGI N/A
- NXTC N/A
- Revenue Next Year
- BGI N/A
- NXTC N/A
- P/E Ratio
- BGI N/A
- NXTC N/A
- Revenue Growth
- BGI N/A
- NXTC N/A
- 52 Week Low
- BGI $0.56
- NXTC $2.69
- 52 Week High
- BGI $2.20
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- BGI 46.14
- NXTC 49.76
- Support Level
- BGI $1.13
- NXTC $8.51
- Resistance Level
- BGI $1.14
- NXTC $13.15
- Average True Range (ATR)
- BGI 0.05
- NXTC 1.30
- MACD
- BGI -0.02
- NXTC -0.29
- Stochastic Oscillator
- BGI 12.56
- NXTC 12.37
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.